Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $13.56 Analyst target: $28.18 Upside: 107.82%
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the development and commercialization of Haduvio to treat serious neurology-mediated conditions. The company is headquartered in New Haven, Connecticut.
See the full interactive analysis & chart →Informational only — not investment advice.